Latest News for: lead compound
Edit
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
News-Press Now 25 Feb 2026
TOKYO--(BUSINESS WIRE)--Feb 25, 2026-- .
Edit
Alchemedicine and Asahi Kasei Pharma Enter Exclusive Global License Agreement for HiSAP Lead Compounds (Asahi Kasei Corporation)
Public Technologies 17 Feb 2026
To learn more, visit https.//www.asahikasei-pharma.co.jp/en/ 1HiSAP lead compounds which are novel and meet Alchemedicine's internal criteria for pharmacology, DMPK, safety, physicochemical properties and potential patentability.
Edit
Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection
Nasdaq Globe Newswire 20 Jan 2026
Preclinical in vivo efficacy data (PoC) in atopic dermatitis of disease-modifying therapy; positive patent opinion from the EU Patent Office ... .
- 1